Prevention of intraventricular haemorrhage: a role for recombinant activated factor VII?
As the survival from extreme prematurity continues to improve, focus on the quality of this survival becomes increasingly important. Prevention of intraventricular haemorrhage (IVH) and its potential long-term sequelae remains one of the major challenges in the early management of these infants. Recombinant activated factor VII (rVIIa), a novel haemostatic agent with an ever-expanding list of potential applications, warrants consideration for use in this setting. This review examines the pathogenesis and prevention of IVH, current concepts of haemostasis both in adults and neonates, and the postulated mechanism of action and various uses of rVIIa. Published data specifically relating to use of rVIIa in neonates is summarised. The hypothesis that early (prophylactic) administration of rVIIa to extremely preterm infants (<28 weeks) would reduce the incidence of severe IVH is explored.
Robertson
Jeremy D
JD
Haematology Department, Queensland Health Pathology Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. jeremy_robertson@health.qld.gov.au
D002543:Cerebral Hemorrhage / Q000503:physiopathology / Q000517:prevention & control*; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006487:Hemostasis; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa